Maxillomandibular Advancement and Upper Airway Stimulation for Treatment of Obstructive Sleep Apnea: A Systematic Review

Ning Zhou 1,2,3,* , Jean-Pierre T. F. Ho 1,2,4,† , René Spijker 5,6, Ghizlane Aarab 3, Nico de Vries 3,7,8, Madeline J. L. Ravesloot 7 and Jan de Lange 1,2

1 Department of Oral and Maxillofacial Surgery, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
2 Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands
3 Department of Orofacial Pain and Dysfunction, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, 1081 LA Amsterdam, The Netherlands
4 Department of Oral and Maxillofacial Surgery, Northwest Clinics, 1815 JD Alkmaar, The Netherlands
5 Medical Library, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
6 Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3584 CG Utrecht, The Netherlands
7 Department of Otorhinolaryngology—Head and Neck Surgery, OLVG, 1061 AE Amsterdam, The Netherlands
8 Department of Otorhinolaryngology—Head and Neck Surgery, Antwerp University Hospital (UZA), 2650 Edegem, Antwerp, Belgium

* Correspondence: n.zhou@amsterdamumc.nl
† These authors contributed equally to this work.

Abstract: This systematic review aimed to comparatively evaluate the efficacy and safety of maxillomandibular advancement (MMA) and upper airway stimulation (UAS) in obstructive sleep apnea (OSA) treatment. A MEDLINE and Embase database search of articles on MMA and/or UAS for OSA was conducted. Twenty-one MMA studies and nine UAS studies were included. All the MMA studies demonstrated a reduction in apnea hypopnea index (AHI) postoperatively, and success rates ranged from 41.1% to 100%. Ten MMA studies reported pre- and postoperative Epworth sleepiness scale (ESS), and all but one study demonstrated a reduction in ESS. In the UAS studies, all but one demonstrated a reduction in AHI, and success rates ranged from 26.7% to 77.8%. In the eight UAS studies reporting pre- and postoperative ESS, an ESS reduction was demonstrated. No studies reported any deaths related to MMA or UAS. The most common postoperative complications after MMA and UAS were facial paresthesia in the mandibular area and discomfort due to electrical stimulation, respectively. This systematic review suggests that both MMA and UAS are effective and generally safe therapies for OSA. However, due to the limitations of the included studies, there is no evidence yet to directly compare these two procedures in OSA treatment.

Keywords: obstructive sleep apnea; therapy; maxillomandibular surgery; hypoglossal nerve; systematic review

1. Introduction

Obstructive sleep apnea (OSA) is a prevalent sleep-related breathing disorder characterized by recurrent upper airway obstruction during sleep [1], and its overall prevalence ranges from 9% to 38% in the general adult population [2]. OSA is associated with considerable health risks, such as cardiovascular and cerebrovascular disease [3,4]. Continuous positive airway pressure (CPAP) is accepted as the first-line therapy for moderate to severe OSA, but poor compliance and suboptimal use of CPAP drive OSA patients to seek alternative therapies, including other non-invasive therapies and surgical treatment [5,6].
Moderate-to-severe OSA is usually caused by multilevel obstructions of the upper airway, which highlights the need for surgical therapies able to resolve multilevel upper airway collapse [7]. One such therapy that has existed for many decades is maxillomandibular advancement (MMA) [8,9]. MMA is a multilevel skeletal surgery in which the maxilla and mandible are advanced by a combination of a Le Fort I osteotomy of the maxilla and a bilateral sagittal split osteotomy of the mandible [8,9]. By expanding the skeletal framework attached with the pharyngeal soft tissues, MMA enlarges the velo-orohypopharyngeal airway [10] and increases the tension of the pharyngeal soft tissues, decreasing the collapsibility of the upper airway [11]. MMA is currently considered as the most effective surgical treatment modality for moderate-to-severe OSA in adults aside from tracheostomy.

A more contemporary therapy is hypoglossal nerve stimulation (HNS), which works by electrically stimulating the branches of the hypoglossal nerves that innervate muscles responsible for protruding the tongue and thus maintaining upper airway patency during sleep [12]. Currently, there are three different systems for HNS therapy, including the Aura6000 Targeted Hypoglossal Neurostimulation system (LivaNova PLC, London, England, UK), the GenioTM system (Nyxoah SA, Mont-Saint-Guibert, Belgium), and the Inspire II upper airway stimulation (UAS) system (Inspire Medical Systems, Maple Grove, MN, USA) [13]. Given that the Inspire UAS system is the most widely used system having Food and Drug Administration (FDA) approval for clinical use [14], this review only focused on UAS therapy (Inspire® system). Over the past decade, UAS has emerged as an effective therapy and therefore has become an increasingly popular treatment option for moderate-to-severe OSA [15,16].

Currently, the main indications for MMA are moderate-to-severe OSA, and mild OSA in patients presenting with a dentofacial deformity [17]. UAS therapy is generally indicated for patients with the following characteristics: moderate-to-severe OSA (apnea hypopnea index (AHI) 15–65 events/h with <25% central or mixed apneas), positive airway pressure (PAP) therapy failure, and absence of complete concentric velum collapse (CCCp) on drug-induced sleep endoscopy (DISE) [18]. When no generally accepted indicative results are found during clinical, laboratory, or endoscopic examinations (e.g., significant skeletal-dental deformity, AHI > 65 events/h, CCCp on DISE), patients with moderate-to-severe OSA may be expected to benefit from MMA as well as UAS therapy. Although MMA and UAS have both demonstrated efficacy and safety for patients, there is a paucity of evidence on comparison of these two treatment options [17].

Therefore, the purpose of this systematic review is to comprehensively evaluate and compare the efficacy of MMA and UAS for moderate-to-severe OSA through the assessment of AHI and Epworth sleepiness score (ESS) as primary outcomes. Secondly, the postoperative complications of these two therapies were investigated.

2. Materials and Methods

This systematic review was performed in accordance with the preferred reporting items for systematic review and meta-analysis (PRISMA) statement [19]. The protocol for this systematic review was registered at PROSPERO (PROSPERO ID: CRD42021261394; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=261394 (accessed on 14 November 2022)).

2.1. Selection Criteria

The inclusion criteria were: (1) adult patients (> 18 years old) with moderate-to-severe OSA diagnosed by polysomnography (PSG; AHI ≥ 15 events/h); (2) patients who underwent MMA or UAS for OSA; (3) studies that reported pre- and postoperative PSG data; (4) studies with a follow-up ≥ 6 months; (5) study designs: randomized controlled trials (RCTs), quasi-experimental studies, and cohort studies; and (6) English language.

The exclusion criteria were: (1) sample size < 10 patients; (2) patients who underwent other adjunctive surgical procedures (e.g., uvulopalatopharyngoplasty) at the time of MMA
or UAS; and (3) preliminary studies in which the findings had been nested in other studies with larger sample size and/or longer follow-up.

2.2. Literature Search

A literature search was performed with the help of an information specialist (RS) using MEDLINE and Embase databases on 14 December 2021. Search terms and search strategies used for each database are available in Supplementary Materials (Table S1 (a)).

2.3. Study Selection

After removal of duplicate articles, the remaining results were screened based on title and abstract by two independent reviewers (NZ and JH). The full texts of potentially relevant articles were retrieved and further evaluated by NZ and JH independently for compliance of studies with the eligibility criteria. Discrepancies were resolved by discussion. Reference lists of eligible studies were checked for additional studies.

2.4. Data Extraction

The extracted data included article title, year of publication, first author, study design, specific surgical technique, length of follow-up, sample size, age, gender, body mass index (BMI), preoperative and postoperative PSG data (AHI, respiratory disturbance index (RDI), and oxygen desaturation index (ODI)), preoperative and postoperative ESS score, preoperative and postoperative data on quality of life (QoL), surgical success rate and cure rate, and postoperative complications. According to the accordion severity grading system of surgical complications [20], the postoperative complications were classified as major or minor depending on the needs for endoscopic or interventional radiologic procedures or reoperation as well as failure of one or more organ systems.

Data were extracted by NZ and JH independently. Discrepancies were resolved through discussion. If RDI was reported by a study, it would be extracted as AHI, since these two respiratory parameters have been consolidated based on the 2013 American Academy of Sleep Medicine’s manual for the scoring of sleep and associated events [21]. If there were multiple follow-up data in a study, the data with longest follow-up time were included. Surgical success was defined as “a postoperative AHI < 20 and at least 50% reduction in AHI after surgery” [22], and surgical cure was defined as “a postoperative AHI < 5” [23].

2.5. Quality Assessment

Methodologic quality assessment of each study was performed by NZ and JH independently, and any discrepancies were resolved by discussion.

The Methodological Index for Non-Randomized Studies (MINORS) quality assessment tool, a validated tool for the methodological assessment of non-randomized surgical studies [24], was used to assess the methodological quality of the included studies. The MINORS tool is composed of eight items applicable to all non-randomized studies and four additional items specifically for comparative studies. Each item was scored as 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate), giving a global ideal score of 24 for comparative studies and 16 for non-comparative studies. For comparative studies, the categorizations are as follows: 0–6, very low quality; 7–10, low quality; 11–15 fair quality; and ≥16, high quality. For non-comparative studies, the categorizations are as follows: 0–4, very low quality; 5–7, low quality; 8–12, fair quality; and ≥13, high quality [25].

2.6. Statistical Analysis

The collected parameters (age, BMI, AHI, ODI, and ESS) were pooled by weighted average and weighted standard deviation [26]. When there were RCTs or comparative studies between MMA and UAS, meta-analyses were performed to compare the overall effect of MMA and UAS in treating OSA. Heterogeneity of the studies was assessed...
using the $I^2$ statistic with a cutoff of 25% (low), 50% (moderate) and 75% (high) [27]. When moderate-to-high heterogeneity was present, a random effects model was adopted; otherwise, a fixed effects model was used. Because some patients may report multiple complications, the complication rate of each study was calculated by dividing the number of events by the number of patients.

3. Results

3.1. Search Results

The flow diagram of study selection progress is summarized in Figure 1. A total of 2952 studies were screened after deduplication, and 212 were retrieved for full-text review.

MMA group. Twenty-one studies [11,28–47] were identified, producing a pooled data set of 581 patients (male 78.5%) with a weighted age of 42.2 ± 11.5 years and a weighted BMI of 28.1 ± 6.4 kg/m². The mean follow-up period from surgery to final postoperative PSG was 25.9 months (range, 6 months–12.5 years). One study [39] was excluded from the analyses for clinical efficacy because the data of a subset of the patients with a longer follow-up period were nested in another included study [38]. The characteristics of these studies are shown in Table 1.

UAS group. In total, nine studies [15,48–55] were identified, yielding 1029 patients (male 96.2%) with a weighted age of 55.1 ± 10.1 years and a weighted BMI of 29.1 ± 4.2 kg/m². The mean follow-up period was 18.8 months (range, 6 months–5 years). The characteristics are summarized in Table 2.

Because there was no RCT or comparative study of MMA and UAS in treating OSA, a meta-analysis could not be performed to compare their overall effect sizes on OSA.

![Figure 1. PRISMA flow diagram of the study selection process.](image-url)
### Table 1. Characteristics of studies on maxillomandibular advancement.

| Study                  | Design | N   | Age (Years) (Mean ± SD) | % Male | Degree of Advancement (mm) (Mean ± SD) | Follow-Up (Mean ± SD) | BMI (Mean ± SD) | AHI (Mean ± SD) | ODI (Mean ± SD) | ESS (Mean ± SD) | % Success | % Cure |
|------------------------|--------|-----|-------------------------|--------|----------------------------------------|-----------------------|----------------|----------------|----------------|----------------|------------|--------|
| Bettego et al., 2000   | Retro  | 20  | 44.4 ± 10.6             | 90     | 11.8 ± 0.5                             | 11.8 ± 0.5            | 6 m           | 26.9 ± 4.3     | 25.4 ± 3.3     | 59.3 ± 29.0     | 11.1 ± 8.9  |         |
| Bianchi et al., 2014   | Retro  | 10  | 45 ± 14                 | 100    | 10                                      | 10                    | 6 m           | 56.8 ± 5.2     | 12.3 ± 5.5     |                |            |         |
| Boyd et al., 2015      | Pro    | 14  | 7.0 ± 2.3               | 92 ± 3.3 | 6.6 ± 2.8 y                             |                       |               | 50.0 ± 20.0    | 8.0 ± 10.7     |                |            |         |
| Conradt et al., 1997   | Retro  | 15  | 44 ± 12                 | 93.3    | >2 y                                   | 28.3 ± 3.4            |               | 51.4 ± 16.9    | 8.5 ± 9.4      |                |            |         |
| Gerbino et al., 2014   | Pro    | 10  | 44.9                    | 9.2 ± 1.2 | 10.4 ± 2.2 | 6 m | 31.6 ± 5.5 | 28 ± 1.4 | 69.8 ± 35.2 | 17.3 ± 16.7 | 59.5 ± 5.3 | 9.1 ± 8 |         |
| Goh et al., 2003       | Pro    | 11  | 42.8 ± 8.2              | 100    | 10                                      | 7.7 m                  | 29.4 ± 4.6    | 27.2 ± 3.3     | 70.7 ± 15.9    | 11.4 ± 7.4     |            |         |
| Goodday et al., 2016   | Retro  | 13  | 37.8 ± 8.6              | 84.6    | 9.6 m                                   | 38.8 ± 10.9           | 37.3 ± 8.0    | 117.9 ± 9.2    | 16.1 ± 26.2    |                | 12.9 ± 5.5 | 5.0 ± 4.1 |
| Hauch et al., 2014     | Pro    | 16  | 33 ± 7.9                | 75      | 12 ± 8 m                                | 22 ± 3.3               |               | 35.7 ± 18      | 4.8 ± 4.4      |                |            |         |
| Kastor et al., 2019    | Pro    | 14  | 51.1 ± 7.3              | 57.1    | 6 m                                     | 25.7 ± 3.7            |               | 40.2 ± 25.6    | 9.9 ± 7.2      | 13.5 ± 18.6    | 4.0 ± 3.5  | 13 ± 6   |
| Li et al., 1999        | Retro  | 175 | 43.5 ± 11.5             | 83      | 6 m                                     | 72.3 ± 26.7           |               | 7.2 ± 7.5      |                |                | 95 ±      |         |
| Li et al., 2000        | Retro  | 40  | 45.6 ± 20.7             | 82.5    | 10.8 ± 2.7                              | 10.8 ± 2.7            | 4.2 ± 2.7 y   | 31.4 ± 6.7    | 32.2 ± 6.3     | 71.2 ± 27.0    | 7.6 ± 5.1  |         |
| Li et al., 2001        | Retro  | 52  | 46.6 ± 6.7              | 82.7    | 10.5 ± 1.5                              | 6 m                    | 32.0 ± 6.0    | 61.6 ± 23.9    | 9.2 ± 8         |                |            |         |
| Li et al., 2002        | Pro    | 12  | 47.3 ± 9.8              | 75      | 10.5 ± 1.2                              | 10.5 ± 1.2            | 6 m           | 33.5 ± 6.2    | 32.3 ± 4.1     | 75.3 ± 26.4    | 10.4 ± 10.8 |         |
| Liao et al., 2015      | Pro    | 20  | 33.4 ± 6.5              | 85      | 14 ± 9.3 m                              | 22.4 ± 3.4            |               | 41.6 ± 19.2    | 5.3 ± 4        |                | 11.9 ± 7.3 | 7 ± 3    |
| Lin et al., 2020       | Pro    | 53  | 35.7 ± 11.7             | 75.7    | 4.3 ± 2.9                               | 13.3 ± 3.8            | 24 m          | 24.8 ± 3.3    | 23.9 ± 4.7     | 34.8 ± 26.0    | 7.4 ± 6.7  |         |
| Liu et al., 2016       | Retro  | 20  | 44 ± 12                 | 85      | 7 ± 1.4                                 | 27 ± 4.6              | 27.4 ± 4.6    | 53.6 ± 26.6    | 9.5 ± 7.4      | 38.7 ± 30.3    | 8.1 ± 9.2 | 17.0 ± 4.8 |
| Rubio-Bueno et al., 2017| Pro   | 34  | 40.8 ± 13.9             | 41.2    | 4.9 ± 3.2                               | 10.4 ± 3.9            | 6 m           | 27.6 ± 4.5    | 25.5 ± 4.3     | 38.3 ± 10.7    | 6.5 ± 4.3  | 34.7 ± 12.5 |
| Veys et al., 2017      | Pro    | 10  | 44.7 ± 9.5              | 80      | 4.8 ± 2.8                               | 8.3 ± 2.3             | 6 m           | 26.8 ± 12.7    | 12.3 ± 14.4    |                |            |         |
| Vicini et al., 2010    | RCT    | 25  | 49.1 ± 9.1              | 92      | 11                                      | 13 ± 2.5 m            | 32.7 ± 5.8    | 31.4 ± 6.5    | 56.8 ± 16.5    | 8.1 ± 7        | 11.6 ± 2.8 | 7.7 ± 1.3 |

Note: ± indicates the standard deviation.
Table 1. Cont.

| Study                        | Design   | N  | Age (Years) (Mean ± SD) | % Male | Degree of Advancement (mm) (Mean ± SD) | Follow-Up (Mean ± SD) | BMI (Mean ± SD) | AHI (Mean ± SD) | ODI (Mean ± SD) | ESS (Mean ± SD) | % Success | % Cure |
|------------------------------|----------|----|-------------------------|--------|----------------------------------------|----------------------|----------------|---------------|----------------|---------------|-----------|--------|
|                              |          |    |                         |        | Max                                    | Mand                 | Pre-op         | Post-op       | Pre-op         | Post-op       | Pre-op    | Post-op |
| Vigneron et al., 2017 [46]   | Retro    | 29 | 40.7 ± 12.6             | 8.4 ± 4.1 | 11.7 ± 5.1 | 12.5 ± 3.5 y | 24.6 ± 4       | 56.6 ± 24     | 25.5 ± 20.6   | 7.5 ± 4.7     | 41.4       |
| Wu et al., 2019 [47]         | Retro    | 28 | 37.2 ± 11.8             | 2.0 ± 3.1 | 8.8 ± 3.7 | 8.4 ± 2.8 | >1 y          | 24.2 ± 5.1     | 13.1 ± 18.3   | 8.8 ± 3.7     | 12.8 ± 2.8   | 6.9 ± 2.5  | 85.7    |

AHI, apnea–hypopnea index (events/h); BMI, body mass index (kg/m²); ESS, Epworth sleepiness scale; m, months; Max, maxilla; Mand, mandible; N, number of patients; ODI, oxygen desaturation index (events/h); post-op, postoperative; pre-op, preoperative; pro, prospective; RCT, randomized controlled trial; retro, retrospective; y, years. a Respiratory disturbance index (RDI) in this study was extracted as AHI. b The number of patients was 9. c This study defined surgical success as an AHI < 15/h with ≥ 50% reduction in postoperative AHI. d This study did not define the criteria of surgical success. e This study defined surgical success as an RDI < 15/h with ≥ 50% reduction in postoperative RDI. f This study defined surgical success as a postoperative RDI < 20/h.

Table 2. Characteristics of studies on upper airway stimulation.

| Study                        | Design   | N  | Age (Years) (Mean ± SD) | % Male | Follow-Up (Month) | BMI (Mean ± SD) | AHI (Mean ± SD) | ODI (Mean ± SD) | ESS (Mean ± SD) | % Success | % Cure |
|------------------------------|----------|----|-------------------------|--------|-------------------|----------------|---------------|----------------|---------------|-----------|--------|
|                              |          |    |                         |        | Pre-op            | Post-op        | Pre-op         | Post-op       | Pre-op         | Post-op       | Pre-op    | Post-op |
| Bachour et al., 2021 [55]    | Retro    | 15 | 52.9 ± 6.6              | 86.7   | 18 ± 9.6          | 30.1 ± 4.5     | 33.0 ± 16.5    | 30.3 ± 21.1    | 11.5 ± 3.8     | 8.1 ± 4.5   | 26.7     |
| Heser et al., 2017 [48]      | Pro      | 20 | 57 ± 12                 | 100    | 12                | 28.1 ± 13.1    | 28.9 ± 7.6     | 6.6 ± 5.1      | 15.9 ± 3.5     | 10.0 ± 6.1  | 77.8     |
| Philip et al., 2018 [49]     | Pro      | 10 | 52.0 ± 9.4              | 100    | 28.8 ± 3.3        | 46.7 ± 12.2    | 14.5 ± 8.9     | 38.1 ± 21.1    | 10.5 ± 9.9     | 15.9 ± 3.5   | 10.6     |
| Steffen et al., 2019 [50]    | Retro    | 18 | 51.5                    | 24     | 27.9 ± 4.5        | 28.0 ± 4.7     | 26.3 ± 10.6    | 10.4 ± 10.1    | 12.8 ± 12.0    | 10.1 ± 12.0  | 12.7 ± 5.2 | 33.3     |
| Steffen et al., 2020 [51]    | Pro      | 38 | 58.0 ± 10.0             | 97.4   | 36                | 29.1 ± 3.9     | 28.6 ± 3.5     | 30.0 ± 13.7    | 13.1 ± 14.1    | 12.1 ± 5.8   | 60.6     |
| Suurna et al., 2021 [54]     | Pro      | 782| 14.3 ± 7.0              | 29.2 ± 4 | 35.8 ± 15.0      | 14.5 ± 14.9    | 11.4 ± 5.5     | 7.1 ± 4.6      | 69.7          |
| Van de Heyning et al., 2012  | Pro      | 28 | 55.1 ± 9.2              | 96.4   | 6                 | 29.5 ± 2.5     | 42.3 ± 16.4    | 32.6 ± 29.1    | 30.7 ± 21.6    | 26.7 ± 27.0  | 11.0 ± 5.0 | 7.6 ± 4.3 |
| Vanderveken et al., 2013 [53]| Retro    | 21 | 55.6 ± 11               | 95.2   | 6                 | 28 ± 2         | 38.5 ± 11.8    | 20.3 ± 20.6    | 8.2 ± 5.0      | 6.4 ± 4.3    | 62       |
| Woodson et al., 2018 [15]    | Pro      | 97 | 54.4 ± 10.3             | 60     | 28.6 ± 2.5        | 30.4 ± 9.4 b   | 12.4 ± 16.3    | 27.2 ± 10.0 b  | 9.9 ± 14.5     | 11.3 ± 5.2   | 6.9 ± 4.7  |

AHI, apnea–hypopnea index (events/h); BMI, body mass index (kg/m²); ESS, Epworth sleepiness scale; N, number of patients; ODI, oxygen desaturation index (events/h); post-op, post-operative; pre-op, pre-operative; pro, prospective; retro, retrospective. a The number of patients was 18. b The number of patients was 71. c The number of patients was 92.
3.2. Quality Assessment

MMA group. One of the included studies was an RCT of MMA and autotitrating positive airway pressure (APAP), one was a retrospective quasi-experimental study, ten were prospective cohort studies, and nine were retrospective cohort studies. As only the MMA cohort of the RCT was included in the analyses, after omitting the unrequired APAP cohort, this study was regarded as a single-arm trial. The quality of the RCT was therefore assessed using the MINORS tool as per the other included studies. Of these, three studies were classified as “high quality”, and the others were classified as “fair quality” (Supplementary Table S2 (a)).

UAS group. Six prospective studies and three retrospective studies were included. Of these, one study was classified as “high quality” and eight studies as “fair quality” (Supplementary Table S2 (b)).

3.3. Respiratory Parameters

MMA group. Fifteen MMA studies [11,28–31,33–37,41,42,44,45,47] reported a significant reduction in AHI postoperatively ($p < 0.05$). The others [32,38,40,43,46] reported an AHI reduction but did not report a $p$ value. All the studies [11,28–38,40–47], totaling 446 patients, demonstrated a weighted baseline AHI of 54.6 ± 27.4/h and a weighted postoperative AHI of 10.1 ± 10.8/h.

Of four studies [11,32,36,43] (n = 78) reporting pre- and postoperative ODI, two demonstrated a significant reduction in ODI after MMA ($p < 0.05$), and the other two also reported an ODI reduction but without a $p$ value. The weighted pre- and postoperative ODIs were 35.1 ± 22.8/h and 6.3 ± 6.4/h, respectively.

UAS group. Of the selected studies, the study by Bachour et al. [55] did not show a significant reduction in AHI postoperatively. Five studies [48–51,54] demonstrated a significant reduction in AHI postoperatively ($p < 0.05$), and three studies [15,52,53] showed an AHI reduction but did not report a $p$ value. The weighted pre- and postoperative AHIs in 1003 patients were 35.2 ± 14.7/h and 15.0 ± 16.1/h, respectively.

Of six studies [15,49–52,55] reporting pre- and postoperative ODI, the study by Bachour et al. [55] did not find a significant improvement in ODI postoperatively, while the others [15,49–52] reported a reduction in ODI after surgery, of which two studies did not report a $p$ value. The weighted pre- and postoperative ODIs were 26.5 ± 16.0/h and 14.6 ± 18.5/h (n = 180), respectively.

3.4. Subjective Parameters

MMA group. Of nine studies [11,34,36,41–45,47] (n = 217) reporting pre- and postoperative ESS, the study from Lin et al. did not show an improvement in ESS after MMA, one study demonstrated a reduction in ESS but without a $p$ value, and the others reported a significant reduction in ESS ($p < 0.05$). The weighted pre- and postoperative ESS values were 13.1 ± 5.5 and 6.7 ± 4.8, respectively.

Three studies [30,42,44] assessed pre- and postoperative QoL. Boyd et al. found that after MMA, there was a significant improvement in the Functional Outcomes of Sleep Questionnaire (FOSQ) ($p < 0.05$) [30]. Veys et al. assessed the subjective outcome of MMA using the OSA QoL questionnaire. They found that there was an improvement in all of the following six symptoms after MMA—daytime sleepiness, snoring, concentration, waking up at night, headache, and high blood pressure—while the influence of MMA on nocturia and sexual activity was variable [44]. Lin et al. found that there was no significant improvement in Short Form-36 quality of life (SF-36) after MMA [42].

UAS group. Of eight studies [15,49–55] reporting pre- and postoperative ESS, seven demonstrated a significant reduction in ESS postoperatively ($p < 0.05$), and one reported an ESS reduction but did not report a $p$ value. The weighted pre- and postoperative ESS values were 11.4 ± 5.4 (n = 1006) and 7.0 ± 4.6 (n = 1001), respectively.

Two studies reported pre- and post-UAS FOSQ scores. The STAR trial cohort demonstrated an increase in FOSQ score five years after surgery (14.3 ± 3.3 to 18.0 ± 2.2). Van
de Heyning et al. also found a significant improvement in FOSQ score postoperatively (89.1 ± 23.5 to 100.8 ± 16.9, p < 0.05).

3.5. Surgical Success and Cure

MMA group. Surgical success rate of MMA was available in 15 studies [11,28,32–35,37,38,40,41,43–47] and ranged from 41.1% to 100%. Surgical cure rate of MMA was reported in seven studies [11,34,42–45,47] and ranged from 36% to 67.9%.

UAS group. Surgical success rate of UAS was available in six studies [15,50–52,54,55], ranging from 26.5% to 77.8%. Surgical cure rate was reported in four studies [15,50,51,55] and ranged from 6.7% to 44%.

3.6. Long-Term Follow-Up Outcomes

MMA group. Five studies [30,31,38,42,46] reported long-term follow-up (≥2 years) data in 151 patients with weighted baseline AHI of 51.7 ± 28.2/h. At a mean follow-up of 5.0 years, the weighted postoperative AHI was 11.1 ± 13.0/h. Only one study [42], with 53 patients, reported long-term follow-up ESS (10.8 ± 5.0 to 10.2 ± 5.1, p > 0.05). Boyd et al. [30] reported a long-term improvement in FOSQ score after MMA. Surgical success rate was reported in two studies [38,46] (90% and 41.4%, respectively), and surgical cure rate was only available in one study [42] (67.9%).

UAS group. Three studies [15,50,51] reported long-term follow-up (≥2 years) data in 127 patients with weighted baseline AHI of 29.7 ± 11.0/h. At a mean follow-up of 4.2 years, the weighted postoperative AHI was 12.3 ± 14.8/h. These three studies [15,50,51] also reported a long-term improvement in ODI and ESS after UAS therapy. One study [15] reported a long-term (five years follow-up) improvement in FOSQ score. Surgical success and cure rates were reported in all three studies [15,50,51] (success rate: 77.8%, 71.1%, and 74.6%, respectively; cure rate: 33.3%, 35%, and 44%, respectively).

3.7. Safety

There were no studies reporting any deaths related to MMA or UAS surgery.

MMA group. Of the included studies, 10 reported participants’ complications after MMA (n = 428) [28,30,33,39,42–47]. The rate of major complication ranged from 0 to 18%. Five studies reported the major complications after MMA, which included reoperations for removal of osteosynthesis screws and plates (n = 8) [30,33,46], reoperations for maxillary non-union (n = 2) [28,46], and acute dyspnea (n = 1) [45].

The most common minor complication reported was facial paresthesia caused by the impairment of inferior alveolar nerve [30,33,39,43,45–47]. Four studies [39,45–47] reported both the rates of transient and persistent paresthesia in mandibular area, which were 100% and 13% (n = 175), 100% and 28% (n = 25), 90% and 60% (n = 34), and 32% and 0% (n = 28), respectively. Additionally, one study [43] (n = 34) reported only the rate of transient paresthesia in mandibular area—75%; one study [33] (n = 11) reported only the rate of the persistent symptom—27%. In the long-term follow-up study from Boyd et al. [30] (n = 30), although no patients exhibited such facial anesthesia as measured objectively, 40% of patients subjectively perceived a decrease in sensation. Facial paresthesia in the infraorbital area was reported by two studies [45,46]. In the study by Vicini et al. [45] (n = 25), the rates of transient and persistent paresthesia in infraorbital area were 100% and 4%, respectively; in the study by Vigneron et al. [46] (n = 34), they were 37% and 30%, respectively.

Excluding facial paresthesia, the other reported minor complications consisted of developed malocclusion [30,45–47] (n = 13), temporomandibular disorders [46,47] (n = 11), local infection [28,30,47] (n = 6), minor postoperative wound pain [33] (n = 2), and others (n = 5) [28,44,47]. Of ten studies [28,30,32,41–47] that investigated patients’ perception of their facial appearance after MMA, two studies [30,46] reported that there were 13% (4/30) and 15% (5/34) patients who perceived worsening of their facial appearance after MMA,
respectively; the others [28,32,41–45,47] reported that the perception of facial appearance was positive or neutral in all the patients after MMA.

UAS group. Of the five studies reporting patients' complications (n = 2051) [15,49,51,52,54], the rate of serious device-related adverse events range from 0 to 7%. Four studies [15,51,52,54] reported a total of 50 serious device-related adverse events requiring surgical repositioning or replacement of the neurostimulator or implanted leads. In addition, in the study from Suurna et al. [54] (n = 1849), 0.4% of the patients reported serious intraoperative adverse events, including but not limited to hematoma (n = 8), infection (n = 2), extra implant procedure (n = 1), intraoperative arrest (n = 1), and pneumothorax (n = 1).

Since one study [54] did not report the count of minor complications, the safety outcomes of a subset of the study population (ADHERE cohort) reported in a previous study [56] were used to analyze the minor complication rate. In that study [56], the rates of minor surgery-related and device-related complications 137 ± 77 days after UAS implant were 6% (18/313) and 22% (69/313), respectively; 386 ± 136 days after UAS implant were 4% (8/217) and 24% (53/217), respectively. In the STAR trial cohort [15] consisting of 126 participants, the rates of minor surgery-related and device-related complication were both 136% (171/126) at the first year; at the fifth year, they were decreased to 1% (1/126) and 16% (20/126), respectively. Van de Heyning et al. [52] reported only minor surgery-related adverse events in their population, which yielded a minor complication rate of 57% (16/28). Philip et al. [49] and Steffen et al. [51] did not report any minor complications in their study populations. The most common minor surgery-related and device-related complications were incision discomfort [15,51,56] and discomfort due to electrical stimulation [15,56], respectively.

4. Discussion

This is the first systematic review aiming to comparatively evaluate MMA and UAS therapy in treating OSA. We reviewed 21 studies on MMA and 9 studies on UAS in treating OSA. Due to the fact that there is no RCT or comparative study of MMA and UAS, a meta-analysis cannot be performed to directly compare these two interventions. Separate analyses of studies on MMA and UAS were utilized for this review. In this review, the trials for MMA tended to be published earlier than those for UAS. Therefore, for some patients in the UAS group, MMA could have been considered at first as an alternative therapy to CPAP and not been chosen. It should be noted that UAS therapy has stricter and clearer inclusion criteria (e.g., 15/h ≤ AHI ≤ 65 /h, absence of CCCp during DISE) [14,17] for patients, especially in comparison to MMA. There is therefore discrepancy of patients' baseline characteristics between the MMA cohort and UAS cohort. In this review, the MMA cohort has younger age and higher baseline AHI compared to the UAS cohort. Moreover, it is impossible for us to compare other patients' characteristics associated with OSA, such as the size of tongue, retrolingual space, and jaw position. To obtain definitive results on the comparison of MMA and UAS, future studies should include comparative studies of these two therapies where participants would have comparable baseline characteristics and be qualified for both therapies. Another point to be noted is that the variations in MMA surgeries are probably greater than in UAS as the training and the lineage of potential variations are much higher in MMA than in UAS.

4.1. Objective Outcomes

Based on the separate analysis of studies on MMA and UAS, we reported that these two procedures are both effective treatment modalities for OSA. However, compared to UAS, MMA seems to be more effective in treating OSA with a more significant decrease in AHI and higher success rate. Through different mechanisms, MMA and UAS have been proven to be able to address multiple sites of collapse simultaneously [11,36]. MMA enlarges the entire pharynx and reduces the collapsibility of the upper airway by advancing the maxillomandibular complex and anterior pharyngeal tissues attached to the maxilla, mandible, and hyoid bone [39]. The mechanism by which UAS resolves multilevel col-
lapse, is enlargement of the retropalatal airway associated with tongue protrusion, which is so called “palatoglossus coupling” phenomenon [48]. Safiruddin et al. found that the retropalatal enlargement in response to UAS was statistically significant only in the responders, while the responders and non-responders had similar degrees of retrolingual opening to stimulation [57]. Therefore, we are of the opinion that the superiority of MMA over UAS in OSA treatment may be associated with the ability of MMA to enlarge the retropalatal airway more significantly. To improve patient selection for MMA and UAS, the mechanism of action of these two surgical procedures and the role of pathogenesis of OSA on the outcome of both surgeries require clarification in future studies.

4.2. Subjective Outcomes

It is interesting to note that several studies [42,55] reported a discordance between objective outcome measures (e.g., AHI) and patient-reported outcome measures, which highlights the importance of subjective outcome evaluation for OSA patients. In contrast to published ESS data, there is a scarcity of evidence related to other subjective outcomes of surgical treatment for OSA. Boyd et al. [30] evaluated the impact of MMA on quality of life (QoL) using the Functional Outcomes of Sleep Questionnaire (FOSQ). Two years after MMA, a significant improvement in mean FOSQ scores of 4.7 was observed. In a study by Woodson et al. [15], the improvements in mean FOSQ scores following UAS were 3.0 at 1 year and 3.7 at 5 years, respectively. In addition to daytime sleepiness and QoL, patient satisfaction—an important measure of therapy quality—should be noted when evaluating treatment options for OSA. Currently, only a few studies have evaluated patient satisfaction with MMA or UAS for the management of OSA [56,58–62]. In a study by Butterfield et al. [59], 95.5% of patients were satisfied with MMA surgery for OSA, 90.9% would repeat the procedure, and 86.4% would recommend MMA to others for OSA treatment. In the ADHERE registry, 94% of patients reported that they were satisfied with UAS therapy and would undergo UAS again, and 93% reported that they would recommend UAS to others [56]. According to the available evidence, both MMA and UAS could significantly improve the perception for OSA patients with high levels of patient satisfaction. However, the comparison of improvement in patient-perceived measures between the two therapies must be addressed in future studies.

4.3. Long-Term Outcomes

The long-term follow-up period of the included MMA studies ranges from 2 years to 12.5 years. Because of the small sample size, one study by Pottel et al. [63] reporting the longest follow-up result of MMA was excluded. In that study, the short term (within 2 years) success rate was 66.67% (8/12), and the long-term (median 19 years; range 14–20 years) success rate of MMA was 44.44% (4/9). Of the nine patients who attended long-term re-evaluation, the median ages at the time of MMA surgery and re-evaluation were 43 years (range 34–63 years) and 62 years (range 49–82 years), respectively. At the long-term follow up, two of the six patients who were initially successfully treated by MMA had relapse of OSA with AHI comparable to preoperative values. Both patients had significant weight gain (+4.1 and +7.9 kg/m²). In a study of 29 OSA patients treated by MMA, Vigneron et al. [46] concluded that the success rate was 85.7% in the immediate postoperative period and 41.1% at 12.5 years. Additionally, they concluded that the good candidates for long-term success of MMA were the young patients (<45 years old) with BMI < 25 kg/m², AHI < 45/h, SNB angle < 75°, narrow retrolingual space (<8 mm), preoperative orthodontics, and without co-morbidity. It has been suggested that long-term failure of MMA might be attributed to weight gain [38,63,64], skeletal relapse [64], and ageing [63]. Given that UAS is an innovative therapy for OSA from the last decade, the longest follow-up period of the UAS studies was 5 years, from the STAR trial [15]. The success rates of UAS in the STAR trial cohort were 66% (83/126), 74% (73/98), and 75% (53/71) at 1, 3, and 5 years, respectively. In UAS therapy for OSA treatment, patients’ adherence is necessary to guarantee clinical efficacy [65]. The STAR trial revealed a high adherence to UAS therapy in the long-term,
with a patient-self-reported nightly device use of 80% at 5 years, which might partially explain the stability of treatment effect. In addition, lower baseline ODI was found to be predictive of 5-year response to UAS therapy. It is therefore concluded that both MMA and UAS were relatively stable treatments for patients with moderate-to-severe OSA. In order to maintain clinical efficacy, more effort is needed to provide continuous follow-up for OSA patients and to ascertain the factors associated with long-term stability of outcomes.

4.4. Safety

In terms of treatment safety, this systematic review revealed that both MMA and UAS were generally safe surgical procedures for OSA, with relatively low rates of major complication. In the included MMA studies, all but one of the major complications were reoperation for removal of hardware. Age has been shown to be a risk factor for increased need for hardware removal [66]. In addition, Passeri et al. found that patients who were active smokers or had a history of smoking had higher risk of complications, which included removal of hardware [67]. The most common minor complication of MMA detailed in the literature was paresthesia of the lower lip and chin. It has been suggested that age at the time of surgery and addition of a genioplasty increase the risk of facial paresthesia, and a large degree of advancement further increases the risk in older patients [68,69]. In the STAR cohort (n = 126), the rates of major complication requiring device explanation, reposition, or replacement were 4% at 4 years and 9.5% at 5 years, indicating that the reoperations after UAS may occur more often during the late time frame. The STAR cohort also suggested that the majority of minor complications after UAS were gradually resolved. Notably, Withrow et al. evaluated the impact of age on safety of UAS and found no significant difference between younger and older cohorts in complication rates [70]. Current evidence suggests that both MMA and UAS appear to be safe approaches in OSA treatment, and compared to MMA, treating OSA with UAS may lead to fewer complications for older patients.

4.5. Clinical Relevance

In patients with moderate to severe OSA and failure of CPAP treatment, a portion of them could qualify for both MMA and UAS therapy. Current evidence shows that MMA may have superior efficacy in OSA treatment. However, MMA is a more invasive intervention, exposing patients to longer recovery time and higher risk of postoperative complications. Overnight admission to the intensive care unit is required for OSA patients following MMA surgery, and the length of hospitalization after MMA reported previously ranged from <2 days to 5–8 days [69]. Additionally, MMA surgery often involves time-consuming preoperative and/or postoperative orthodontic work. One notable potential problem with MMA has been the accompanying alteration in facial appearance; however, most patients undergoing MMA for OSA view the change in facial appearance as neutral or even positive [30,32,46]. In comparison to MMA, UAS surgery is less invasive and more patient-friendly and does not require extended recovery. The majority of patients are discharged the same day or one day after UAS surgery [71]. In addition to the information regarding treatment efficacy and safety, the cost of treatment options is important in assisting decision-making in OSA treatment. It has been indicated that UAS is cost-effective, with a lifetime incremental cost effectiveness ratio (ICER) of USD 39,471 per quality-adjusted life year (QALY) in the United States healthcare system [72] and EUR 44,446 per QALY in a European setting [73]. However, to our knowledge, no study has assessed the cost-effectiveness of MMA, which precludes the comparison of cost-effectiveness between these two therapies. Hence, to further assist decision-making in OSA treatment, there is a need to assess and compare the costs and cost-effectiveness of each intervention.

Since the primary target patient population differs between MMA and UAS, these two procedures are usually not put on par in the current practice guidelines. In the current Stanford protocol, UAS and MMA are considered phase I and phase II surgical procedures, respectively [74]. It has been proposed that these two procedures might be considered as complementary therapies [17]. For example, UAS may be considered when a patient...
fails to respond to MMA or for a patient with relapse of OSA after previously successful MMA [75]. It is interesting to note that in a recent study [76], Sarber et al. evaluated the efficacy of UAS therapy in 18 OSA patients who did not meet all FDA criteria for UAS and found promising treatment outcomes. They suggested that future studies must consider the expansion of current FDA criteria for UAS, particularly in BMI and AHI criteria. Thus, to optimize surgical outcomes, reduce rates of mortality and morbidity, and improve quality of life and other subjective outcomes, further investigation is essential to clarify indications of each therapy for OSA.

In addition to MMA and UAS, there are other evidence-based therapeutic options for OSA, which include behavioral strategies (e.g., weight loss), medical therapy (e.g., CPAP), other surgical options, and adjuvant therapy (e.g., pharyngeal muscle training) [77,78]. Of the non-CPAP therapies for OSA, more invasive procedures, such as MMA, are not well accepted. Oral appliances offer a non-invasive option for managing OSA, the most common of which are mandibular advancement devices (MADs). MADs modify the position of the jaw, the tongue, and other supporting structures of the upper airway, thereby increasing upper airway volume and preventing collapse of the upper airway [79]. MADs are recommended as a first-line therapy for mild-to-moderate OSA and for severe OSA after CPAP failure, intolerance, or refusal [80]. Growing evidence suggests that MADs could achieve favorable outcomes regardless of the severity of OSA [81,82].

In the era of precision medicine, the interconnected risk factors for OSA must be considered in order to achieve precision medicine in OSA [78]. The combined modern therapies for OSA must be adjusted continuously in respect to recent scientific research in order to deliver the best results for patients, emphasizing their quality of life in addition to medical care. Therefore, any of the therapies may either have an important role as monotherapy in the treatment of OSA or could be used in combination with the other therapies. The greater the complexity of a clinical case, the greater the need for multidisciplinary collaboration.

4.6. Limitations

There are several limitations of the present review. Firstly, because of the inherent difficulty of randomizing patients to different surgical interventions or sham surgery [83], except for one RCT and one quasi-experimental trial, all the included studies were cohort studies, the majority of which demonstrated fair quality according to the MINORS tool. Due to the lack of RCT and comparative studies of MMA and UAS for OSA, a meta-analysis cannot be performed to directly compare these two procedures. Additionally, meta-analyses were not conducted to separately assess overall effect sizes of MMA and UAS therapy on OSA, as mean and SD of the difference between pre- and postoperative measures were absent in majority of the selected studies. In this review, we performed separate analyses for MMA and UAS studies, combined with noticeable differences between the two cohorts in age and OSA severity, which prevented us from generating a solid conclusion on the comparison of these two procedures. Due to the fact that some patients may fall between two stools, comparison of the two procedures is important. Future studies should include quasiexperimental trials and comparative cohort studies comparing MMA and UAS to better clarify which modality is superior in OSA treatment. These studies can be part of a future large international consortium, which is more likely to generate solid conclusions. Secondly, due to the implemented inclusion criteria, which included the presence of both preoperative and postoperative PSG data, some well-conducted studies reporting on only subjective outcomes and/or safety were excluded for this study. Therefore, the present analysis of subjective outcomes and safety may not be entirely representative of the population undergoing MMA or UAS in the current literature. Lastly, our review is exclusively based on studies published in English, which can introduce a language bias [84].

5. Conclusions

The results presented in this review suggest that both MMA and UAS are effective and generally safe surgical treatment modalities for patients with moderate-to-severe OSA.
However, within the limitation of the selected studies, there is currently no evidence on the comparison of MMA and UAS in the treatment of OSA.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11226782/s1, Table S1: (a) Search strategy in MEDLINE database. (b) Search strategy in Embase database; Table S2: (a) Methodological appraisal of the individual studies according to MINORS assessment tool—maxillomandibular advancement surgery. (b) Methodological appraisal of the individual studies according to MINORS assessment tool—upper airway stimulation.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** Author G.A. receives research grants from Sunstar Suisse SA and Vivisol-ResMed and is an unpaid member of the academic advisory board for Oral Function (Sunstar Suisse SA); author N.d.V is member of the Medical Advisory Board of NightBalance and consultant to Philips Healthcare, Inspire, and Nyxoah; the other authors declare they have no conflicts of interest. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

**References**

1. Jordan, A.S.; McSharry, D.G.; Malhotra, A. Adult obstructive sleep apnoea. *Lancet* 2014, 383, 736–747. [CrossRef]
2. Senaratna, C.V.; Perret, J.L.; Lodge, C.J.; Lowe, A.J.; Campbell, B.E.; Matheson, M.C.; Hamilton, G.S.; Dharmage, S.C. Prevalence of obstructive sleep apnea in the general population: A systematic review. *Sleep Med. Rev.* 2017, 34, 70–81. [CrossRef] [PubMed]
3. Bagai, K. Obstructive sleep apnea, stroke, and cardiovascular diseases. *Neurologist* 2010, 16, 329–339. [CrossRef] [PubMed]
4. Knauret, M.; Naik, S.; Gillespie, M.B.; Kryger, M. Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. *World J. Otorhinolaryngol. Head Neck Surg.* 2015, 1, 17–27. [CrossRef]
5. Gottlieb, D.J.; Punjabi, N.M. Diagnosis and Management of Obstructive Sleep Apnea: A Review. *JAMA* 2020, 323, 1389–1400. [CrossRef]
6. Rotenberg, B.W.; Vicini, C.; Pang, E.B.; Pang, K.P. Reconsidering first-line treatment for obstructive sleep apnea: A systematic review of the literature. *J. Otolaryngol. Head Neck Surg.* 2016, 45, 23. [CrossRef]
7. Sharifian, M.R.; Zarrinkamar, M.; Alimardani, M.S.; Bakhshaei, M.; Asadpour, H.; Morovatdar, N.; Amini, M. Drug Induced Sleep Endoscopy in Obstructive Sleep Apnea. *Tanaffos* 2018, 17, 122–126.
8. Li, K.K. Surgical management of obstructive sleep apnea. *Clin. Chest Med.* 2003, 24, 365–370. [CrossRef]
9. Riley, R.W.; Powell, N.B.; Gillelemault, C.; Nino-Murcia, G. Maxillary, mandibular, and hyoid advancement: An alternative to tracheostomy in obstructive sleep apnea syndrome. *Otolaryngol. Head Neck Surg.* 1986, 94, 584–588. [CrossRef]
10. Gokce, S.M.; Gorgulu, S.; Gokce, H.S.; Bengi, A.O.; Karacayli, U.; Ors, F. Evaluation of pharyngeal airway space changes after bimaxillary orthognathic surgery with a 3-dimensional simulation and modeling program. *Am. J. Orthod. Dentofac. Orthop.* 2014, 146, 477–492. [CrossRef]
11. Liu, S.Y.; Huon, L.K.; Iwasaki, T.; Yoon, A.; Riley, R.; Powell, N.; Torre, C.; Capasso, R. Efficacy of Maxillomandibular Advancement Examined with Drug-Induced Sleep Endoscopy and Computational Fluid Dynamics Airflow Modeling. *Otolaryngol. Head Neck Surg.* 2016, 154, 189–195. [CrossRef] [PubMed]
12. Strollo, P.J.; Soose, R.J.; Maurer, J.T.; de Vries, N.; Cornelius, J.; Froymovich, O.; Hansson, R.D.; Padhya, T.A.; Steward, D.L.; Gillespie, M.B.; et al. Upper-Airway Stimulation for Obstructive Sleep Apnea. *N. Engl. J. Med.* 2014, 370, 139–149. [CrossRef] [PubMed]
13. Steffen, A.; Heiser, C.; Galetke, W.; Herkenrath, S.D.; Maurer, J.T.; Günther, E.; Stuck, B.A.; Woehrle, H.; Löbler, J.; Randerath, W. Hypoglossal nerve stimulation for obstructive sleep apnea: Updated position paper of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. *Eur. Arch. Oto-Rhino-Laryngol.* 2022, 279, 61–66. [CrossRef]
14. Vanderveken, O.M.; Beyers, J.; Op de Beeck, S.; Dietlijns, M.; Willemen, M.; Verbraecken, J.A.; De Backer, W.A.; Van de Heyning, P.H. Development of a Clinical Pathway and Technical Aspects of Upper Airway Stimulation Therapy for Obstructive Sleep Apnea. *Front. Neurosci.* 2017, 11, 523. [CrossRef]
15. Woodson, B.T.; Strohl, K.P.; Soose, R.J.; Gillespie, M.B.; Maurer, J.T.; de Vries, N.; Padhya, T.A.; Badr, M.S.; Lin, H.S.; Vanderveken, O.M.; et al. Upper Airway Stimulation for Obstructive Sleep Apnea: 5-Year Outcomes. *Otolaryngol. Head Neck Surg.* 2018, 159, 194–202. [CrossRef] [PubMed]
16. Dedhia, R.C.; Strollo, P.J.; Soose, R.J. Upper Airway Stimulation for Obstructive Sleep Apnea: Past, Present, and Future. *Sleep* 2015, 38, 899–906. [CrossRef]
17. Yu, M.S.; Ibrahim, B.; Riley, R.W.; Liu, S.Y. Maxillomandibular Advancement and the Upper Airway: Extrapharyngeal Surgery for Obstructive Sleep Apnea. Clin. Exp. Otorhinolaryngol. 2020, 13, 225–233. [CrossRef]
18. Mashaqi, S.; Patel, S.J.; Combs, D.; Estep, L.; Helmick, S.; Machamer, J.; Parthasarathy, S. The Hypoglossal Nerve Stimulation as a Novel Therapy for Treating Obstructive Sleep Apnea—A Literature Review. Int. J. Environ. Res. Public Health 2021, 18, 1642. [CrossRef]
19. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Bousquet, I.; Hoffmann, T.C.; Mulrow, C.D.; Shami, S.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 2021, 372, n160. [CrossRef]
20. Strasberg, S.M.; Linehan, D.C.; Hawkins, W.G. The accordion severity grading system of surgical complications. Ann. Surg. 2009, 250, 177–186. [CrossRef]
21. Berry, R.B.; Brooks, R.; Gamaldo, C.E.; Harding, S.M.; Lloyd, R.M.; Marcus, C.L.; Vaughn, B.V. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.0.2; American Academy of Sleep Medicine: Darien, IL, USA, 2013.
22. Sher, A.E.; Schechtman, K.B.; Piccirillo, J.F. The efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndrome. Sleep 1996, 19, 156–177. [CrossRef] [PubMed]
23. Elshaug, A.G.; Moss, J.R.; Southcott, A.M.; Hiller, J.E. Redefining success in airway surgery for obstructive sleep apnea: A meta analysis and synthesis of the evidence. Sleep 2007, 30, 461–467. [CrossRef] [PubMed]
24. Slim, K.; Nini, E.; Forestier, D.; Kwiatkowski, F.; Panis, Y.; Chipponi, J. Methodological index for non-randomized studies (minors): Development and validation of a new instrument. ANZ J. Surg. 2003, 73, 712–716. [CrossRef] [PubMed]
25. Shah, A.; Memon, M.; Kay, J.; Wood, T.J.; Tushinski, D.M.; Khanna, V. Preoperative Patient Factors Affecting Length of Stay following Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. J. Arthroplast. 2019, 34, 2124–2165. [CrossRef] [PubMed]
26. Altman, D.G.; Machin, D.; Bryant, T.N.; Gardner, M.J. Statistics with Confidence: Confidence Intervals and Statistical Guidelines, 2nd ed.; BMJ Books: London, UK, 2000; p. 254.
27. Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327, 557–560. [CrossRef] [PubMed]
28. Bettge, G.; Pepin, J.L.; Veale, D.; Deschaux, C.; Raphael, B.; Levy, P. Obstructive sleep apnea syndrome. fifty-one consecutive patients treated by maxillofacial surgery. Am. J. Respir. Crit. Care Med. 2000, 162, 641–649. [CrossRef] [PubMed]
29. Bianchi, A.; Betti, E.; Tarsitano, A.; Morselli-Labate, A.M.; Lancellotti, L.; Marchetti, C. Volumetric three-dimensional computed tomographic evaluation of the upper airway in patients with obstructive sleep apnoea syndrome treated by maxillomandibular advancement. Br. J. Oral Maxillofac. Surg. 2014, 52, 831–837. [CrossRef] [PubMed]
30. Boyd, S.B.; Walters, A.S.; Waite, P.; Harding, S.M.; Song, Y. Long-Term Effectiveness and Safety of Maxillomandibular Advancement for Treatment of Obstructive Sleep Apnea. J. Clin. Sleep Med. 2015, 11, 699–708. [CrossRef]
31. Conradt, R.; Hochban, W.; Brandenburg, U.; Heitmann, J.; Peter, J.H. Long-term follow-up after surgical treatment of obstructive sleep apnoea by maxillomandibular advancement. Eur. Respir. J. 1997, 10, 123–128. [CrossRef]
32. Gerbino, G.; Bianchi, F.A.; Verzé, L.; Ramieri, G. Soft tissue changes after maxillo-mandibular advancement in OSAS patients: A three-dimensional study. J. Cranio-Maxillofac. Surg. 2014, 42, 66–72. [CrossRef] [PubMed]
33. Goh, Y.H.; Lim, K.A. Modified maxillomandibular advancement for the treatment of obstructive sleep apnea: A preliminary report. Laryngoscope 2003, 113, 1577–1582. [CrossRef] [PubMed]
34. Goodday, R.H.; Bourque, S.E.; Edwards, P.B. Objective and Subjective Outcomes Following Maxillomandibular Advancement Surgery for Treatment of Patients With Extremely Severe Obstructive Sleep Apnea (Apnea-Hypopnea Index >100). J. Oral Maxillofac. Surg. 2016, 74, 583–589. [CrossRef] [PubMed]
35. Hsieh, Y.J.; Liao, Y.F.; Chen, N.H.; Chen, Y.R. Modified maxillomandibular advancement for obstructive sleep apnoea. J. Clin. Med. 2022, 11, 6782. [CrossRef] [PubMed]
42. Lin, C.H.; Chinn, W.C.; Huang, Y.S.; Wang, P.F.; Li, K.K.; Pirelli, P.; Chen, Y.H.; Guilleminault, C. Objective and subjective long term outcome of maxillomandibular advancement in obstructive sleep apnea. *Sleep Med*. 2020, 79, 289–296. [CrossRef]

43. Rubio-Bueno, P.; Landete, P.; Ardanaz, B.; Vazquez, L.; Soriano, J.B.; Wix, R.; Capote, A.; Zamora, E.; Ancochea, J.; Naval-Gías, L. Maxillomandibular advancement as the initial treatment of obstructive sleep apnoea: Is the mandibular occlusal plane the key? *Int. J. Oral Maxillofac. Surg*. 2017, 46, 1363–1371. [CrossRef] [PubMed]

44. Vey, B.; Pottel, L.; Mollemans, W.; Abeloo, J.; Swennen, G.; Neyt, N. Three-dimensional volumetric changes in the upper airway after maxillomandibular advancement in obstructive sleep apnoea patients and the impact on quality of life. *Int. J. Oral Maxillofac. Surg*. 2017, 46, 1525–1532. [CrossRef] [PubMed]

45. Vicini, C.; Dallan, I.; Campanini, A.; De Vito, A.; Barbanti, F.; Giorgiomarrano, C.; Bossi, M.; Plazzi, G.; Provini, F.; Lugaresi, E. Surgery vs ventilation in adult severe obstructive sleep apnea syndrome. *Am. J. Otolaryngol*. 2010, 31, 14–20. [CrossRef] [PubMed]

46. Vigneron, A.; Tamisier, R.; Orset, E.; Pepin, J.L.; Bettega, G. Maxillomandibular advancement for obstructive sleep apnea syndrome treatment: Long-term results. *J. Craniomaxillofac*. 2017, 45, 183–191. [CrossRef] [PubMed]

47. Wu, Q.; Wang, Y.; Wang, P.; Xiang, Z.; Ye, B.; Li, J. The inverted-L ramus osteotomy versus sagittal split ramus osteotomy in maxillomandibular advancement for the treatment of obstructive sleep apnea patients: A retrospective study. *J. Craniomaxillofac*. Surg. 2019, 47, 1839–1847. [CrossRef]

48. Heiser, C.; Edenharter, G.; Bas, M.; Wirth, M.; Hofauer, B. Palatoglossus coupling in selective upper airway stimulation. *Laryngoscope* 2017, 127, E378–E383. [CrossRef]

49. Philip, P.; Heiser, C.; Bioulac, S.; Altene, E.; Penchet, G.; Cinry, E.; Hofauer, B.; Monteyrol, P.J.; Micoulaud-Franchi, J.A. Hypoglossal nerve stimulation on sleep and level of alertness in OSA: A preliminary study. *Neurology* 2018, 91, e615–e619. [CrossRef]

50. Steffen, A.; Abrams, N.; Suurna, M.V.; Wollenberg, B.; Hasselbacher, K. Upper-Airway Stimulation Before, After, or Without Uvulopalatopharyngoplasty: A Two-Year Perspective. *Laryngoscope* 2019, 129, 514–518. [CrossRef]

51. Steffen, A.; Sommer, U.J.; Maurer, J.T.; Abrams, N.; Hofauer, B.; Heiser, C. Long-term follow-up of the German post-market study for upper airway stimulation for obstructive sleep apnea. Sleep Breath. 2020, 24, 979–984. [CrossRef]

52. Van de Heyning, P.H.; Badr, M.S.; Baskin, J.Z.; Cramer Bornemann, M.A.; De Backer, W.A.; Dotan, Y.; Hohenhorst, W.; Knaack, L.; Lin, H.S.; Maurer, J.T.; et al. Implanted upper airway stimulation device for obstructive sleep apnea. *Laryngoscope* 2012, 122, 1626–1633. [CrossRef]

53. Vanderveken, O.M.; Maurer, J.T.; Hohenhorst, W.; Hamans, E.; Lin, H.S.; Vroegop, A.V.; Anders, C.; de Vries, N.; Van de Heyning, P.H. Evaluation of drug-induced sleep endoscopy as a patient selection tool for implanted upper airway-stimulation for obstructive sleep apnea. *Clin. J. Sleep Med*. 2013, 9, 433–438. [CrossRef] [PubMed]

54. Suurna, M.V.; Steffen, A.; Boon, M.; Chio, E.; Copper, M.; Patil, R.D.; Green, K.; Hanson, R.; Heiser, C.; Huntley, C.; et al. Impact of Body Mass Index and Discomfort on Upper Airway Stimulation: ADHERE Registry 2020 Update. *Laryngoscope* 2021, 131, 2616–2624. [CrossRef] [PubMed]

55. Bachour, A.; Bäck, L.; Pietarinen, P. No changes in nocturnal respiration with hypoglossal neurostimulation therapy for obstructive sleep apnoea. *Clin. Respir. J.* 2021, 15, 329–335. [CrossRef] [PubMed]

56. Heiser, C.; Steffen, A.; Boon, M.; Hofauer, B.; Doghmraj, K.; Maurer, J.T.; Sommer, U.J.; Soose, R.; Strollo, P.J., Jr.; Schwab, R.; et al. Post-approval upper airway stimulation predictors of treatment effectiveness in the ADHERE registry. *Eur. Respir. J.* 2019, 53, 1801405. [CrossRef]

57. Safiruddin, F.; Vanderveken, O.M.; de Vries, N.; Maurer, J.T.; Lee, K.; Ni, Q.; Strohl, K.P. Effect of upper-airway stimulation for obstructive sleep apnoea on airway dimensions. *Eur. Respir. J.* 2015, 45, 129–138. [CrossRef]

58. Li, K.K.; Riley, R.W.; Powell, N.B.; Gervacio, L.; Troell, R.J.; Guilleminault, C. Obstructive sleep apnea surgery: Patient perspective and polysomnographic results. *Otolaryngol. Head Neck Surg.* 2000, 123, 572–575. [CrossRef]

59. Butterfield, K.J.; Marks, P.L.; McLean, L.; Newton, J. Quality of life assessment after maxillomandibular advancement surgery for obstructive sleep apnea. *J. Oral Maxillofac. Surg*. 2016, 74, 1228–1237. [CrossRef]

60. Beranger, T.; Garreau, E.; Ferri, J.; Raouil, G. Morphological impact on patients of maxillomandibular advancement surgery for the treatment of obstructive sleep apneaa-hypopnea syndrome. *Int. Orthod.* 2017, 15, 40–53. [CrossRef]

61. Cillo, J.E.; Robertson, N.; Dattilo, D.J. Maxillomandibular Advancement for Obstructive Sleep Apnea Is Associated With Very Long-Term Overall Sleep-Related Quality-of-Life Improvement. *J. Oral Maxillofac. Surg.* 2020, 78, 109–117. [CrossRef]

62. Mehra, R.; Steffen, A.; Heiser, C.; Hofauer, B.; Withrow, K.; Doghmraj, K.; Boon, M.; Huntley, C.; Soose, R.J.; Stevens, S.; et al. Upper Airway Stimulation versus Untreated Comparators in Positive Airway Pressure Treatment-Refractory Obstructive Sleep Apnea. *Ann. Am. Thorac. Soc.* 2020, 17, 1610–1619. [CrossRef]

63. Pottel, L.; Neyt, N.; Hertegonne, K.; Pevernagie, D.; Vey, B.; Abeloo, J.; De Clercq, C. Long-term quality of life outcomes of maxillomandibular advancement osteotomy in patients with obstructive sleep apnoea syndrome. *J. Oral Maxillofac. Surg.* 2019, 48, 332–340. [CrossRef]

64. Riley, R.W.; Powell, N.B.; Li, K.K.; Troell, R.J.; Guilleminault, C. Surgery and obstructive sleep apnea: Long-term clinical outcomes. *Otolaryngol. Head Neck Surg.* 2000, 122, 415–421. [CrossRef] [PubMed]

65. Hofauer, B.; Steffen, A.; Knopf, A.; Hasselbacher, K.; Heiser, C. Patient experience with upper airway stimulation in the treatment of obstructive sleep apnea. Sleep Breath. 2019, 23, 235–241. [CrossRef] [PubMed]

66. Peacock, Z.S.; Lee, C.C.; Klein, K.P.; Kaban, L.B. Orthognathic surgery in patients over 40 years of age: Indications and special considerations. *J. Oral Maxillofac. Surg*. 2014, 72, 1995–2004. [CrossRef] [PubMed]
67. Passeri, L.A.; Choi, J.G.; Kaban, L.B.; Lahey, E.T. Morbidity and Mortality Rates After Maxillomandibular Advancement for Treatment of Obstructive Sleep Apnea. *J. Oral Maxillofac. Surg.* 2016, 74, 2033–2043. [CrossRef]

68. Van Sickels, J.E.; Hatch, J.P.; Dolce, C.; Bays, R.A.; Rugh, J.D. Effects of age, amount of advancement, and genioplasty on neurosensory disturbance after a bilateral sagittal split osteotomy. *J. Oral Maxillofac. Surg.* 2002, 60, 1012–1017. [CrossRef]

69. Zhou, N.; Ho, J.P.T.F.; Huang, Z.; Spijker, R.; de Vries, N.; Aarab, G.; Lobbezoo, F.; Ravesloot, M.J.L.; de Lange, J. Maxillomandibular advancement versus multilevel surgery for treatment of obstructive sleep apnea: A systematic review and meta-analysis. *Sleep Med. Rev.* 2021, 57, 101471. [CrossRef]

70. Withrow, K.; Evans, S.; Harwick, J.; Kezirian, E.; Strollo, P. Upper Airway Stimulation Response in Older Adults with Moderate to Severe Obstructive Sleep Apnea. *Otolaryngol. Head Neck Surg.* 2019, 161, 714–719. [CrossRef]

71. Murphey, A.W.; Baker, A.B.; Soose, R.J.; Padyha, T.A.; Nguyen, S.A.; Xiao, C.C.; Gillespie, M.B. Upper airway stimulation for obstructive sleep apnea: The surgical learning curve. *Laryngoscope* 2016, 126, 501–506. [CrossRef]

72. Pietzsch, J.B.; Liu, S.; Garner, A.M.; Kezirian, E.J.; Strollo, P.J. Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR Trial. *Sleep* 2015, 38, 735–744. [CrossRef]

73. Pietzsch, J.B.; Richter, A.-K.; Randerath, W.; Steffen, A.; Liu, S.; Geisler, B.P.; Wasem, J.; Biermann-Stallwitz, J. Clinical and economic benefits of upper airway stimulation for obstructive sleep apnea in a European setting. *Respiration* 2019, 98, 38–47. [CrossRef] [PubMed]

74. Liu, S.Y.; Awad, M.; Riley, R.; Capasso, R. The Role of the Revised Stanford Protocol in Today’s Precision Medicine. *Sleep Med. Clin.* 2019, 14, 99–107. [CrossRef] [PubMed]

75. Liu, S.Y.; Riley, R.W. Continuing the Original Stanford Sleep Surgery Protocol from Upper Airway Reconstruction to Upper Airway Stimulation: Our First Successful Case. *Laryngoscope* 2016, 126, 501–506. [CrossRef]

76. Sarber, K.M.; Chang, K.W.; Ishman, S.L.; Epperson, M.V.; Dhanda Patil, R. Hypoglossal Nerve Stimulator Outcomes for Patients Outside the U.S. FDA Recommendations. *Laryngoscope* 2020, 130, 866–872. [CrossRef] [PubMed]

77. Trăistaru, T.; Pantea, M.; Tâncu, A.M.C.; Imre, M. Elements of Diagnosis and Non-surgical Treatment of Obstructive Sleep Apnea in Adults from the Dental Medicine Perspective. In *Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy*; Larrivee, D., Ed.; IntechOpen: London, UK, 2021.

78. Carberry, J.C.; Amatoury, J.; Eckert, D.J. Personalized Management Approach for OSA. *Chest* 2018, 153, 744–755. [CrossRef]

79. Chan, A.S.; Sutherland, K.; Schwab, R.J.; Zeng, B.; Petocz, P.; Lee, R.W.; Darendeliler, M.A.; Cistulli, P.A. The effect of mandibular advancement on upper airway structure in obstructive sleep apnoea. *Thorax* 2010, 65, 726–732. [CrossRef]

80. Ramar, K.; Dort, L.C.; Katz, S.G.; Lettieri, C.J.; Harrod, C.G.; Thomas, S.M.; Chervin, R.D. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. *J. Clin. Sleep Med.* 2015, 11, 773–827. [CrossRef]

81. Lee, C.H.; Mo, J.H.; Choi, I.J.; Lee, H.J.; Seo, B.S.; Kim, D.Y.; Yun, P.Y.; Yoon, I.Y.; Won Lee, H.; Kim, J.W. The mandibular advancement device and patient selection in the treatment of obstructive sleep apnea. *Arch. Otolaryngol. Head Neck Surg.* 2009, 135, 439–444. [CrossRef]

82. Vecchierini, M.F.; Attali, V.; Collet, J.M.; d’Ortho, M.P.; Goutorbe, F.; Kerbrat, J.B.; Leger, D.; Lavergne, F.; Monaca, C.; Monteyrol, P.J.; et al. Mandibular advancement device use in obstructive sleep apnea: ORCADES study 5-year follow-up data. *J. Clin. Sleep Med.* 2021, 17, 1695–1705. [CrossRef]

83. Cook, J.A. The challenges faced in the design, conduct and analysis of surgical randomised controlled trials. *Trials* 2009, 10, 9. [CrossRef]

84. Higgins, J.P.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. *Cochrane Handbook for Systematic Reviews of Interventions*, 2nd ed.; John Wiley & Sons: Chichester, UK, 2019; pp. 182–183.